RECENT POSTS
- Your First Move For Friday December 5th
- Web Extra: Fast & Furious Trades For Friday
- Bear Market Boot Camp, Pt. 2
- Fast Message - We Answer Your About T-Bills, Chesapeake Energy...
- Pops & Drops: Credit Suisse, Starbucks...
- It’s A Matter Of Trust
- When Will Hedge Funds Stop Selling
- Which Industries Will Drive Growth?
- Your First Move For Friday December 5th
FAST MONEY FEATURES
FAST MONEY POLLGet in the post game. Respond to our
"Question of the Day" right now.
TRADER RADAR Which stock should be on your screen? Follow the clues to solve this puzzle.
TRADE SCHOOLGrab a pencil because school is in session and the Fast Money traders are teaching class.
EMERGING MONEY TOP 20
Fast Money's index for the world.
FAST MONEY PODCASTSDownload Fast Money onto your MP3 Player.
FAST MONEY WIDGETGrab this all-in-one application and get recaps of the show sent right to your desktop or blog.
SHOP FOR FAST MONEY MERCHANDISEGet your game on with Fast Money gear.
FAST MONEY PHOTOS!Check out our scrapbook. These "pix" are guaranteed winners.
NEWSLETTERSign up and receive a recap email every Friday after the show!
FAST MONEY MOBILE ALERTSGet advanced information about the next Fast Money.
Text Size 
 |
] shares fell more than 8 percent on Monday after data from an important diabetes meeting sparked concern about competition to the company's flagship Byetta medicine which Amylin sells with Eli Lilly [LLY
Loading...
()
]. Byetta has been the only drug on the market in the GLP-1 class of medicines that stimulate the release of insulin only when glucose levels become too high. They also lead to modest weight loss, which is seen as an advantage over other types of diabetes medicines, because obesity is a leading cause of the disease.
The drop continued a slide for Amylin, which fell more than 8 percent on Friday after Novo Nordisk [NOVO
Loading...
()
] released data showing its experimental drug liraglutide outperformed Byetta in a clinical trial.
I’d still watch Amylin, counsels Pete Najarian. They’re working on a once-a-week treatment for diabetes and if they have positive results the stock could surge.
Check Out These Other Posts |
______________________________________________________
Got something to to say? Send us an e-mail at and your comment might be posted on the Rapid Recap. If you'd prefer to make a comment but not have it published on our website send your e-mail to .
Trader disclosure: On June 9, 2008, the following stocks and commodities mentioned or intended to be mentioned on CNBC’s Fast Money were owned by the Fast Money traders; Macke Owns (EMC), (ATVI), (INTC), (WMT), (MSFT), (DIS); Pete Najarian Owns (AAPL), (BKC), (TSO), (XLF), (HPQ), (AMLN); Pete Najarian Owns (AA) Calls, (GME) Calls; Pete Najarian Owns (LEH) Puts; Finerman Owns (GS); Finerman's Firm Owns (AAPL), (MSFT), (TSO), (VLO); Finerman's Firm And Finerman Own (C) And (C) Leaps; Finerman's Firm Owns SPX Index Puts; Finerman's Firm Is Short (IYR), (IJR), (MDY), (SPY), (IWM); Seymour Owns (AAPL), (AA), (INTC), (MER), (TIE), (TSO), (F); Seygem Asset Management Owns (EEM), (HAL), (TTM), (MBT), (GAF)
Del.icio.us
Digg It
Data is a real-time snapshot *Data is delayed at least 15 minutes